The goal of this study is to determine the effectiveness of pegozafermin in treating patients with nonalcoholic steatohepatitis (). The good news for investors in ETNB stock is that it was incredibly effective as a treatment for NASH.
89bio reports that pegozafermin saw high statistical significance with its 44mg every two weeks and 30mg weekly doses. That saw it surpass the primary histology endpoints provided by the Food and Drug Administration (FDA).
Arun J. Sanyal, MBBS, M.D., Professor of the Departments of Medicine, Physiology, and Molecular Pathology at Virginia Commonwealth University, said the following about the news:
“I was pleased to see the impressive results on the critical histology endpoints and non-invasive tests in the ENLIVEN trial. I was especially encouraged by the significant improvement in fibrosis relative to placebo, as fibrosis is a key driver of NASH disease progression which can lead to cirrhosis and other negative clinical outcomes.”
What’s Next For ETNB Stock?
89bio is excited about the results of this clinical trial and wants to continue the development of pegozafermin. This has it seeking aid from the FDA in launching a Phase 3 clinical trial for the drug.
If pegozafermin continues to perform well in clinical trials, it would go a long war toward the commercialization of the treatment. If that happens, investors can expect shares of ETNB stock to rise higher.
ETNB stock is up 33.8% as of Wednesday morning.
There’s more recent stock market news traders can read about below!
We’ve got all of the hottest stock market stories investors need to know about on Wednesday! Among that is what has shares of WaveDancer (NASDAQ:WAVD), Cerberus Cyber Sentinel (NASDAQ:CISO), and GameStop (NYSE:GME) stock moving today. All of that news is available at the following links!
More Wednesday Stock Market News
- Why Is WaveDancer (WAVD) Stock Down 7% Today?
- Why Is Cerberus Cyber Sentinel (CISO) Stock Down 12% Today?
- Why Is GameStop (GME) Stock Up 48% Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.